BRAF and metastatic colorectal cancer: It has been suggested that in order for metastatic colorectal cancer patients to receive a response for treatment with monoclonal antibodies targeting EGFR (panitumumab and cetuximab, Figure 1C), the BRAF gene needs to be present as wild-type (37, 38).